{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-09-29",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "product_ndc": "70709-191",
      "generic_name": "Nilotinib",
      "labeler_name": "Cycle Pharmaceuticals Ltd",
      "brand_name": "CAVHANZA",
      "active_ingredients": [
        {
          "name": "NILOTINIB",
          "strength": "60 mg/1"
        }
      ],
      "finished": true,
      "packaging": [
        {
          "package_ndc": "70709-191-12",
          "description": "112 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (70709-191-12)",
          "marketing_start_date": "20260630",
          "sample": false
        }
      ],
      "listing_expiration_date": "20271231",
      "openfda": {
        "manufacturer_name": [
          "Cycle Pharmaceuticals Ltd"
        ],
        "rxcui": [
          "2747509",
          "2747516",
          "2747518",
          "2747520"
        ],
        "spl_set_id": [
          "98b197ea-bca4-427e-8737-97f70a3262bc"
        ],
        "is_original_packager": [
          true
        ],
        "upc": [
          "0370709191126"
        ],
        "nui": [
          "N0000175605",
          "N0000020009",
          "N0000187062",
          "N0000182137",
          "N0000187064",
          "N0000187063",
          "N0000191272",
          "N0000185503"
        ],
        "pharm_class_epc": [
          "Kinase Inhibitor [EPC]"
        ],
        "pharm_class_moa": [
          "Bcr-Abl Tyrosine Kinase Inhibitors [MoA]",
          "Cytochrome P450 2C8 Inhibitors [MoA]",
          "Cytochrome P450 2D6 Inhibitors [MoA]",
          "Cytochrome P450 2B6 Inducers [MoA]",
          "Cytochrome P450 2C8 Inducers [MoA]",
          "UGT1A1 Inhibitors [MoA]",
          "P-Glycoprotein Inhibitors [MoA]"
        ],
        "unii": [
          "F41401512X"
        ]
      },
      "marketing_category": "NDA",
      "dosage_form": "TABLET, ORALLY DISINTEGRATING",
      "spl_id": "8991c94b-a4c1-46f8-aafe-a106aba4f8cf",
      "product_type": "HUMAN PRESCRIPTION DRUG",
      "route": [
        "ORAL"
      ],
      "marketing_start_date": "20260630",
      "product_id": "70709-191_8991c94b-a4c1-46f8-aafe-a106aba4f8cf",
      "application_number": "NDA217379",
      "brand_name_base": "CAVHANZA",
      "pharm_class": [
        "Bcr-Abl Tyrosine Kinase Inhibitors [MoA]",
        "Cytochrome P450 2B6 Inducers [MoA]",
        "Cytochrome P450 2C8 Inducers [MoA]",
        "Cytochrome P450 2C8 Inhibitors [MoA]",
        "Cytochrome P450 2D6 Inhibitors [MoA]",
        "Kinase Inhibitor [EPC]",
        "P-Glycoprotein Inhibitors [MoA]",
        "UGT1A1 Inhibitors [MoA]"
      ]
    }
  ]
}